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Structural protein VP3FMDV O1 subtype undergoes antigenic variation under diverse growth conditions. Of particular interest is the
amino acid variation observed at position 56 within the structural protein VP3. Selective pressures inﬂuence
whether histidine (H) or arginine (R) is present at this position, ultimately inﬂuencing in vitro plaque
morphology and in vivo pathogenesis in cattle. Using reverse genetics techniques, we have constructed FMDV
type O1 Campos variants differing only at VP3 position 56, possessing either an H or R (O1Ca-VP3-56H and
O1Ca-VP3-56R, respectively), and characterized their in vitro phenotype and virulence in the natural host. Both
viruses showed similar growth kinetics in vitro. Conversely, they had distinct temperature-sensitivity (ts) and
displayed signiﬁcantly different pathogenic proﬁles in cattle and swine. O1Ca-VP3-56H was thermo stable and
induced typical clinical signs of FMD, whereas O1Ca-VP3-56R presented a ts phenotype and was nonpathogenic
unless VP3 position 56 reverted in vivo to either H or cysteine (C).se Center, USDA/ARS/NAA, P.O.
323 3006.
ccone).
sevier Inc.© 2011 Published by Elsevier Inc.Introduction
Foot-and-mouth disease (FMD) is an infectious viral disease that
affects cloven-hoofed animals, including cattle, sheep, pigs, goats,
camelids and deer. Its wide host range and rapid spread make FMD an
international animal health concern, since all countries are vulnerable
to accidental or intentional trans-boundary introduction (Grubman and
Baxt, 2004; Rowlands, 2003). The disease is caused by foot-and-mouth
disease virus (FMDV), an Aphthoviruswithin the viral family Picornaviri-
dae that exists as seven immunologically distinct serotypes: O, A, C, Asia
1, and South African Territories (SAT) type 1, SAT2, and SAT3. The viral
genome consists of a single-stranded, positive sense RNA of about
8200 nucleotides (nt). The open reading frame (ORF) encodes a
long polyprotein that is processed by virus-encoded proteases into
four structural proteins (VP1 through 4) and eight non-structural
proteins (L, 2A, 2B, 2C, 3A, 3B, 3C and 3D) (Belsham, 1993; Ryan et al.,
1989). Due to high error rates inherent in RNA replication, viral
RNA genomes display a high level of nucleotide variation (Drake
and Holland, 1999; Figlerowicz et al., 2003) that can affect replication
speed (Jarousse et al., 1994; Nunez et al., 2001; Pelletier et al., 1998;
Zhang et al., 1995), virulence (Conenello et al., 2007; Zurbriggen et al.,
1989), antigenicity or biochemical properties (Li et al., 2010; Martin-Acebes et al., 2010;Mateu et al., 1990; Szepanski et al., 1992). The avail-
ability of infectious cDNA picornavirus clones provides an opportunity
to manipulate speciﬁc genomic mutations and examine their effects
on viral infection.
The genetic and antigenic variation has been extensively studied
for FMDV both in ﬁeld virus samples and laboratory cell-passed
isolates (Carrillo et al., 2007; Cottam et al., 2009; Haydon et al.,
2001; Meyer et al., 1994; Piatti et al., 1995; Sevilla et al., 1996).
For type O viruses selective pressures inﬂuence whether a histidine
(H) or arginine (R) residue is present at position 56 of VP3. It has
been reported that an R amino acid (aa) in position 56 of VP3 (R56) is
acquired after serial passage in BHK-21 cells (Kitson et al., 1990;
Marquardt et al., 1991) and that this mutation correlates with a
small plaque phenotype, a marker indicative of virus attenuation in
mice (Jensen andMoore, 1993). Indeed, Sa-Carvalho et al. (Sa-Carvalho
et al., 1997) constructed a type A chimera virus expressing the O1
Campos structural proteins carrying, among others aa substitutions,
R56 in VP3 and demonstrated that this virus exhibited a small plaque
phenotype in cells andwas highly attenuated in bovines. These authors
suggested that adaptation of typeO1 viruses to cell culture results in the
ability of the virus to utilize heparin sulfate (Jackson et al., 1996) as a
receptor with a concomitant loss in virulence. In view of this data,
Rodriguez-Pulido et al. (Rodriguez Pulido et al., 2009) introduced
an R56H substitution in VP3 of an O1 Kaufbueren infectious cDNA
clone (pO1K) to induce reversion of an attenuated phenotype. However,
RNA transcripts derived from pO1K containing H56 did not exhibit
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carrying R56, indicating that the substitution itself was not sufﬁcient to
revert to the attenuated phenotype (Baranowski et al., 2003). It should
be noted that no complete genomic sequence was determined for
the viruses constructed in these previous works, so it is possible
that additional residue substitutions may have affected these results.
Among the FMDV subtype O1 genomic sequences reported to
GenBank, only the amino acids R or H are found in position 56 of VP3;
however, the passage history of these viruses is unclear. Furthermore,
there are no pathogenicity studies using viruses containing these
sequences. The O/JPN/2000 strain isolated in the 2000 Japan out-
break exhibited a mild pathogenicity in bovines, and two different
viral plaque phenotypes of this strain appeared after two passages in
primary bovine cells. Genomic sequencing of the structural proteins
revealed two aa substitutions (VP2 D133N and VP3 H56R) in themildly
pathogenic small plaque viruswhen compared to the large plaque virus
in sucklingmice (Kanno et al., 2002;Morioka et al., 2008). Nevertheless,
these two mutations did not account for the characteristics of another
PanAsia strain isolated from China (Bai et al., 2010). This study demon-
strated that the BHK-21 cell-adapted O/Fujian/CHA/5/99 strain had
high virulence in suckling mice and formed larger plaques than the
bovine-isolated O/Tibet/CHA/1/99, while sequence analysis revealed
that both strains carried a D residue in position 133 of VP2 and an H
in position 56 of VP3.
To clarify the role of these amino acids in FMDV virulence, we
mutated the aa at position 56 of VP3 in a full-length infectious
cDNA clone derived from the FMDV O1 Campos/Bra/58 strain andFig. 1. Construction of the full-length cDNA clone of FMDV O1Campos/Bra/58 strain and in v
diagram of the FMDV genome (8168 nucleotides, (Pereda et al., 2002)) showing the polyC ta
below the genome represent the RT-PCR fragments used for the generation of the full-length
A T7 RNA polymerase promoter was added at the 5′ end of the viral cDNA as well as a unique
is also indicated. The mutations at position 2713 CAT→CGC resulting in the substitution of a
of pO1Ca digested with selected enzymeswere translated in a rabbit reticulocyte system and th
prime.Molecular weightmarkers and cleavage products are indicated on the right and left,
previously described (Piccone et al., 2010) was used as marker (lane 1).evaluated the biological properties and virulence of these viruses
in swine and cattle. Our results demonstrate that identical viruses
differing only in aa residue 56 of VP3, H56 (O1Ca-VP3-56H) or R56
(O1Ca-VP3-56R), had similar growth kinetics in BHK-21 and LF-BK
cells and slight differences in plaque size in BHK-21, LF-BK, IBRS-2
and LK cells. In contrast, the viruses displayed very different patho-
genicities in two natural host species. Virus O1Ca-VP3-56H induced
typical clinical signs of FMD in swine and cattle, whereas virus O1Ca-
VP3-56R was innocuous unless it reverted to either H or cysteine
(C) at VP3-56 during the animal infection. These results clearly
demonstrate that the presence of R56 in VP3 is associated with virus
attenuation during infections in natural host animals.Results
Generation and characterization of pO1Ca
The full-length cDNA clone pO1Ca was constructed by overlapping
PCR fragments ﬂanked by unique restriction enzymes as described in
Materials and methods and shown schematically in Fig. 1A. The full-
length cDNA was preceded by the T7 polymerase promoter and two
additional G residues to improve transcription efﬁciency (Rieder
et al., 1993) and followed by a polyA tail of 15 residues and a unique
EcoRV site. Plasmid containing the substitution H56R in VP3 derived
from the infectious clone pO1Ca was constructed as described in
Materials and methods.itro translation of derivative RNA transcripts. (A) At the top of the ﬁgure is a schematic
il (Cn) and the polyA (An) tail at the end of the 3′ untranslated region (UTR). The boxes
cDNA clone (named pO1Ca) including the restriction sites used in the cloning strategy.
EcoRV site at the 3′ end to allow the synthesis of RNA transcripts. Restriction site EcoRI
a H by R at position 56 of VP3 are indicated. (B) RNAs derived from in vitro transcription
e productswere then analyzed by PAGE on a 15% gel. Truncated proteins are indicated by a
respectively. O1 Campos infected BHK-21 cell extract labeled with (35S) methionine as
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synthesis, RNA transcripts derived from EcoRV-linearized plasmid
were translated in vitro using reticulocyte lysates as described by
Piccone et al. (1995). To facilitate the identiﬁcation of the viral pro-
teins, pO1Ca was digested with selected restriction enzymes that
remove the downstream portion of the viral genome from the plasmid
facilitating the interpretation of the viral protein pattern using SDS-
PAGE. Fig. 1B shows that the polyprotein derived from transcripts of
pO1Ca was processed into the virus precursors and mature proteins,
indicating its ability to undergo viral proteolytic processing.In vitro characterization of the infectious clone-derived viruses
RNA transcript derived from pO1Ca-VP3-56H or pO1Ca-VP3-56R
was used to transfect BHK-21 cells by electroporation, and then
supernatant from transfected cells was subjected to serial passage
in LF-BK αVβ6 cells to amplify the clone-derived viruses. Sequencing
of the entire genome of recovered viruses (O1Ca-VP3-56H and O1Ca-
VP3-56R) veriﬁed that they were identical to the parental DNAs,
conﬁrming that only the predicted mutations were incorporated
into the viruses. Sequencing results also revealed that nt changes
in the third position of codons 55 and 57 (ﬂanking position 56) of
VP3 introduced during the construction of pO1Ca-VP3-56R were
retained (data not shown), excluding the possibility of contamination
by the parental virus.
The in vitro growth characteristics of viruses O1Ca-VP3-56H and
O1Ca-VP3-56R were comparatively evaluated in multi-step growth
curves in BHK-21 and LF-BK cells. Cells were infected at a low (0.01)
or high (10) MOI and samples were collected at times post-infection
through 24 h. The results shown in Fig. 2A demonstrate that both
viruses exhibited similar growth characteristics and reached comparable
titers in these cell lines. Additionally, the plaque size and morphology of
these viruses was analyzed in a standard plaque assay in cells from
different origins (Fig. 2B). Both viruses produced a similar plaque
size in BHK-21 cells, while virus O1Ca-VP3-56R produced smaller
plaques compared to O1Ca-VP3-56H in IBRS-2 and LF-BK cells, but
clearly larger plaques compared to O1Ca-VP3-56H in LK cells.Fig. 2. In vitro characterization of the FMDV O1Ca-VP3-56H and O1Ca-VP3-56R recovered vir
MOI 0.01 in BHK-21 and LF-BK (upper panel), or MOI 10 at 37 °C and 41 °C in LF-BK (bottom
temperature. Virus yield was determined by TCID50/ml at the time points indicated. The ﬁ
O1Ca-VP3-56H and O1Ca-VP3-56R viruses in BHK-21, LF-BK, LK and IBRS-2 cells. Infected c
at 48 h post infection. Plaques from appropriate dilutions are shown.Virulence assessment of FMDV O1Ca-VP3-56H and O1Ca-VP3-56R
in cattle
Virulence of both viruses in cattle was assessed utilizing a well
established intradermolingual inoculation method (Henderson, 1949).
Two cows were inoculated with 104 PFU/animal of either O1Ca-VP3-
56H or O1Ca-VP3-56R, and infection and clinical signs were monitored
daily as described by Pacheco andMason (2010). Results demonstrated
that the two animals inoculated with the O1Ca-VP3-56H strain (#42
and #43) developed clinical FMD and reached the maximum clinical
score (4 feet affected with vesicles) by 2 or 3 days post-inoculation
(dpi). Both animals displayed fever (N40 °C) from 2 to 4 or to 6 dpi.
Viremia lasted 4 to 5 days, starting at 1 dpi. Virus shedding was
detected in nasal swabs from both animals beginning at 1 dpi to
the end of the collection period (7 dpi) (Fig. 3). Sequence analysis
of the P1 polyprotein conﬁrmed that viruses collected from secondary
replication sites exhibited no differences from the inoculated virus
(data not shown). Interestingly, cows inoculated with O1Ca-VP3-56R
(#44 and #45) showed no clinical signs, no fever, no viremia and no
virus shedding (Fig. 3). Additionally, no serum neutralizing antibodies
were detected 2 months after inoculation, no virus was isolated from
probangs and no transmission occurred to two cows that were in direct
contact since 1 dpi (results not shown). These results suggest that
O1Ca-VP3-56R does not undergo any detectable replicationwhen inoc-
ulated into animals.Virulence assessment of FMDV O1Ca-VP3-56H and O1Ca-VP3-56R
in swine
To examine the effect of H and R amino acids at position 56 of VP3
on virus virulence in pigs, six animals were intradermally inoculated
with approximately 104 PFU/animal of either O1Ca-VP3-56H or
O1Ca-VP3-56R (Figs. 4 and 5, respectively) and monitored for clinical
disease. All animals infected with O1Ca-VP3-56H (#01 through #06)
developed classic FMD disease. Animals became febrile, depressed,
lame and developed lesions in the non-inoculated feet and mouth.
By the second week post-inoculation, the disease had subsided anduses. (A) In vitro growth curves at 37 °C of O1Ca-VP3-56H and O1Ca-VP3-56R viruses at
panel). Cells were inoculated with the indicated MOI, and incubated at the described
gure is representative of two independent experiments. (B) Plaques corresponding to
ells were incubated at 37 °C under a tragacanth overlay and stained with crystal violet
Fig. 3. Assessment of O1Ca-VP3-56H and O1Ca-VP3-56R virus virulence in cattle. Steers were intradermolingual (IDL) inoculated with 104 PFU of either O1Ca-VP3-56H (animal #42
and #43) or O1Ca-VP3-56R SK6 (animal #44 and #45). Presence of clinical signs (clinical scores), rise in body temperature over 40 °C (+), and virus yield (quantiﬁed as log10 of
viral RNA copies/ml of sample) in blood and nasal swabs were daily determined during a seven day observational period.
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of viremia, detected by real-time RT-PCR, demonstrated the presence
of virus in blood starting on the ﬁrst day of disease peaking by day 2
to 3. Virus was also detected by rRT-PCR in nasal swabs of all 6
animals starting as early as 2 dpi and peaking at 2 to 4 dpi. Conversely,
the six animals inoculated with O1Ca-VP3-56R (#07 through #12)
presented a heterogeneous phenotype. Two of the animals (#11
and #12) did not display any FMD-related symptoms, presenting as
clinically normal throughout the entire experimental period. According-
ly, no virus could be detected in the bloodor nasal swabs of these animals
at any test time points. Conversely, the other four animals inoculated
with O1Ca-VP3-56R presented a disease that was nearly indistinguish-
able in intensity compared to that observed in animals infected with
O1Ca-VP3-56H, differing only by a slight delay in the course of the dis-
ease (approximately by 1–3 days). Consequently, in these four animals
viremia kinetics was also delayed by a similar lag of time in relation to
the appearance of clinical symptoms (Fig. 5).
Partial RNA sequencing of the viruses isolated from animals was
performed to evaluate the genetic stability of the inoculated virus
during the infection in vivo. All virus isolates from local lesions in
animals inoculated with O1Ca-VP3-56H presented an H at position
56 of VP3. As mentioned earlier, no virus was isolated from animals
infected with O1Ca-VP3-56R that did not develop disease. Interestingly,
all viruses isolated from the four symptomatic animals infected with
O1Ca-VP3-56R possessed a mutation at position 56 of VP3; in three of
them R was substituted by H and in the fourth case by C (data not
shown). The above results indicate that animals inoculated with
O1Ca-VP3-56R remain asymptomatic unless R at position 56 mutates
to either an H or a C.Effect of R at position 56 of VP3 on thermal stability
Since temperature sensitivity has been linked with attenuation
phenotype for FMDV (Butrapet et al., 2000; Omata et al., 1986), viruses
O1Ca-VP3-56H and O1Ca-VP3-56R were analyzed for their ability to
produce plaques at 41 °C, a non-permissive temperature. Using
ten-fold dilutions of the virus stocks, plaque assays were performed
at low MOI and, after adsorption at 37 °C, cells were incubated at either
37 °C or 41 °C for 48 h. While virus O1Ca-VP3-56H displayed a slight
reduction in the number of plaques at 41 °C regarding those detected
at 37 °C, virus O1Ca-VP3-56R failed to produce plaques in LF-BK cells
at all dilutions tested (between 10−2 and 10−6) (data not shown).
To further characterize the effect of temperature on the viruses'
growth, LF-BK cells were infected at a high MOI (MOI=10) and
incubated at 41 °C. Both viruses achieved lower titers at all tested
time points at 41 °C compared to 37 °C (Fig. 2A). In addition, virus
O1Ca-VP3-56R grew slower than virus O1Ca-VP3-56H but reached
similar ﬁnal yield, indicating that the substitution H56R had no signif-
icant effect on virus production.
To further test the temperature sensitivity of these viruses, samples
were heated up to 24 h at either 37 °C or 41 °C and aliquots were taken
at different time points during the heat treatment and titrated on LF-BK
cells. Infectivity titers of FMDV O1Ca-VP3-56R virus were strongly
reduced at both temperatures when compared with O1Ca-VP3-
56H. An approximately 4 logs reduction titer was observed after
heating for 8 h at 37 °C or after 4 h at 41 °C (Fig. 6). Moreover, to deter-
mine if H56 confers a better ﬁtness to the viral population at a higher
temperature, a serial passage experiment was performed in LF-BK cells
at 41 °C with these viruses. Sequencing analysis revealed that after
Fig. 4. Assessment of O1Ca-VP3-56H virus virulence in swine. Six pigs (animal #01 through #06) were intradermically inoculated into the foot bulb with 104 PFU of O1Ca-VP3-56H.
Presence of clinical signs (clinical scores), rise in body temperature over 40 °C (+), and virus yield (quantiﬁed as log10 of viral RNA copies/ml of sample) in blood and nasal swabs
were daily determined during a seven day observational period.
41M.V. Borca et al. / Virology 422 (2012) 37–45three passages virus O1Ca-VP3-56R acquired an H codon at position 56,
whereas virus O1Ca-VP3-56H conserved the original sequence (Table 1).
The presented results indicate that the H56R substitution in VP3 drasti-
cally reduces the thermal stability of the virus.
Discussion
Previous works have suggested that the H56R substitution is
acquired during the process of virus adaptation to cell cultures,
conferring an attenuated phenotype in mice and bovines with an
increased afﬁnity for heparin (Baranowski et al., 2003; Jackson et
al., 1996; Jensen and Moore, 1993; Rodriguez Pulido et al., 2009;
Sa-Carvalho et al., 1997). In fact, R56 of VP3 is the critical viral residue
used for recognition of the cellular heparin sulfate (HS) co-receptor
by different strains of FMDV, as seen in the structure of the serotype
O1BFS in complex with various glycosaminoglycans (Fry et al., 1999).
Nevertheless, none of these studies have assayed the infectivity of type
O transcripts or viruses exclusively differing in the aa residue at
position 56 of VP3 (either H or R) in the natural host. The purpose
of this study was to experimentally demonstrate the role of each of
these amino acids in this particular position on viral virulence in
the natural host. To this end, recombinant viruses were created by
modifying a full-length infectious cDNA clone of the O1 Campos/
Bra/58 strain to introduce either H or R at VP3-56. Viruses O1Ca-
VP3-56H and O1Ca-VP3-56R recovered after electroporation of BHK-
21 cells showed similar growth kinetics and small differences in
plaque sizes in cell culture. In contrast, these viruses displayed a
marked difference in thermal inactivation at 41 °C. In vitro heating
of the viruses caused a pronounced loss of infectivity for virus
O1Ca-VP3-56R compared to O1Ca-VP3-56H, suggesting a role for
the aa at VP3-56 in the thermal stability of the virion. At this tem-
perature, plaque assays also showed signiﬁcant differences betweenboth viruses at higher dilutions, although at MOI 10 they replicate
to similar titers. These results suggest that the substitution H56R
may affect the capsid assembly or stability of the virion. Amino
acid 56 of VP3 is a surface partially exposed residue, which also par-
ticipates in interactions with VP1 and VP2 residues that stabilize the
FMDV protomer (Fig. 7A). Hence, having an H instead of an R at this
position may affect such interactions (Fig. 7B, C). Further experiments
are necessary to validate this assumption. In any case, H56 likely in-
creased the thermal stability of the virus, since after two passages of
O1Ca-VP3-56R in cell culture at 41 °C VP3-R56 changed to VP3-H56.
On the other hand, the identiﬁcation of aa that increase the thermal
stability of the virion without disrupting its infectivity could support
the rational engineering of FMD vaccines (Mateo et al., 2003, 2008).
Another major difference between O1Ca-VP3-56H and O1Ca-VP3-
56R relates to their ability to cause disease in the natural host. Princi-
pally, cattle inoculated with O1Ca-VP3-56H showed typical clinical
signs of FMD, while cattle inoculated with O1Ca-VP3-56R did not
display any clinical signs of disease. Furthermore, no neutralizing
antibodies or virus in blood or saliva was detected in animals inoculated
with O1Ca-VP3-56R. Since both viruses differ only in the aa at position
56 of VP3, this data clearly indicates that the presence of R56 is respon-
sible for the attenuation of O1Ca-VP3-56R in cattle. Additionally, the vir-
ulence of both viruses was tested in swine. All animals inoculated with
O1Ca-VP3-56H exhibited clinical signs of FMD while those inoculated
with O1Ca-VP3-56R remained clinically normal with the exception of
some animals that developed delayed FMD. Interestingly, the virus
recovered from lesions in these animals had a R56C or R56H mutation
and no other mutations in their protein coding region, conﬁrming the
involvement of R56 in viral attenuation. Similar VP3 R to H or C substi-
tutions were previously reported by Sa-Carvalho et al. (1997) in A24/O1
Campos chimeric viruses recovered from infected cattle, although addi-
tional substitutions accompanied that at position 56 of VP3.
Fig. 5. Assessment of O1Ca-VP3-56R virus virulence in swine. Six pigs (animal #07 through #12) were intradermically inoculated into the foot bulb with 104 PFU of O1Ca-VP3-56R.
Presence of clinical signs (clinical scores), rise in body temperature over 40 °C (+), and virus yield (quantiﬁed as log10 of viral RNA copies/ml of sample) in blood and nasal swabs
were daily determined during a seven day observational period.
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and VP3 proteins, in close contact with the C-terminus of VP1, near
the icosahedral three-fold axis. Structural comparisons between
O1BFS and O1K, having R and H in position 56 of VP3, respectively,
demonstrated important changes at the capsid surface between the
two strains (Lea et al., 1995). These changes may explain the different
properties exhibited by viruses carrying R or H in VP3-56 such as
reactivity with MAbs (Kitson et al., 1990; Sa-Carvalho et al., 1997)
or thermal stability properties. Additional studies with subtype
O1 viruses have shown that R56 of VP3 increases the positive charge
of the viral surface at this site and strongly enhances binding to nega-
tively charged HS (Fry et al., 1999; Jackson et al., 1996). Fry et al.
(1999) hypothesized that the high afﬁnity to HS presumably hampers
the spread of infection by sequestering viruses from the targetFig. 6. Temperature sensitivity of O1Ca-VP3-56H and O1Ca-VP3-56R viruses. Virus
stocks were heated up to 24 h at either 37 °C or 41 °C and aliquots were taken at different
times during the heat treatment and titrated on LF-BK cells. Infectivity titers are
expressed in TCID50/ml. Threshold of detection is log101.80 TCID50/ml.cells/tissues. Consistent with this hypothesis, a virus carrying R56
cannot develop virulent infections in vivo unless it undergoes a
reversion to H or C, reducing HS afﬁnity.Materials and methods
Cell lines and virus
Baby hamster kidney (BHK-21) cells, secondary lamb kidney (LK)
cells, bovine kidney (LF-BK) cells (Swaney, 1988) and a derivative
LF-BK cell line expressing the bovine αVβ6 integrin (LF-BK αVβ6)
(LaRocco et al., unpublished data) were maintained as previously
described (Piccone et al., 2010). Growth kinetics and plaque assaysTable 1
Sequence comparison around the position VP3-56 between O1Ca-VP3-56H and O1Ca-
VP3-viruses ampliﬁed at different temperatures.
O1Ca-VP3-56H O1Ca-VP3-56R
Passage 0 ctA cAT ttT ctg cgc ttc
L H F L R F
Passage 3 at 37 °C ctA cAT ttT ctg cgc ttc
L H F L R F
Passage 3 at 41 °C ctA cAT ttT ctg cAc ttc
L H F L H F
Virus stocks were passaged three times in LF-BK cells at MOI 10 and the temperature
indicated. Changes in nucleotides and amino acid sequence are compared with
original virus (Passage 0).
Fig. 7. (A) Ribbon diagram showing the structure of a FMDV pentamer with the position of the ﬁve-fold, three-fold and two-fold icoshedral axes explicitly indicated. The biological
protomer is shown with standard coloring for the proteins VP1 (blue), VP2 (green), VP3 (red) and VP4 (yellow). The rest of the pentamer is shown in gray. Residue 56 of VP3 is
shown as a space ﬁlling surface in cyan. (B, C, D) Close up of the interactions involving the position 56 of VP3, when the residue is R (B), H (C) and C (D). Hydrogen bonds are
depicted as discontinuous lines and the residues involved are explicitly labeled. Coordinates are taken from O1BFS (PDB id 1FOD). H and C were modeled using the program
coot (Emsley and Cowtan, 2004) with the preferred side chain rotamer conformation.
43M.V. Borca et al. / Virology 422 (2012) 37–45were performed also as described previously (Piccone et al., 1995).
The FMDV strain O1Campos/Bra/58 was obtained from the Institute of
Virology at the National Agricultural Technology Institute, Argentina.
Construction of the FMDV O1 Ca full-length cDNA clone and derivative
Total RNA from FMDV-infected BHK-21 cells was isolated with the
TRIzol® system (Life-Technologies), and reverse transcribed by
standard methods using random hexamers (PROMEGA) and Super-
Script II reverse transcriptase (Life-Technologies). cDNA fragments
were ampliﬁed with the Expand High Fidelity PCR system (Roche
Applied Science, Indianapolis, IN) using primers on unique restriction
sites naturally found in the FMDV O1Campos/Bra/58 sequence. All
nucleotide numbering included in this study refers to the sequence
deposited in GenBank under accession number AJ320488.
A total of 4 fragments covering the complete viral genome were am-
pliﬁed (Fig. 1A). The 3′ and 5′ ends of the viral genome as well as the in-
troduction of the polyC tail were obtained by a RACE-PCR technique. For
the 3′ end, a 40mer primer (5′GAATTCCATATGgatatcT15GATTAAG3′)
complementary to the 3′ end of the viral genome, including 15
adenine residues, followed by an adaptor sequence containing
an EcoRV site (lower case) was used for priming the cDNA synthe-
sis. Thereafter, PCR was performed using sense primer nt 5416-5′
GGCAGCAATTgaattcTTT3′ on a unique EcoRI site (lower case) and
antisense primer 5′GAATTCCATATGgatatc3′ complementary to the
adaptor sequence.
For the 5′ end, PCR was performed using sense primer 5′
GGAATTCcatagTAATACGACTCACTATAGGTTGAAAGGGGGCGCTAGGC3′,
which contained the sequences of a NdeI site (lower case), T7 promoter
(underlined), two additional G nucleotides (bold) and 19 nucleotidesof the 5′ end of the viral genome; and antisense primer nt 350-
5′TTggatccTGAAAGGCGGGCGTCGGG3′ which incorporated a StyI
site (lower case). To add the polyC tail, the PCR reaction was
carried out using sense primer 5′ TtcctaggC17TAGGTTTTACCGTCATTCCC
which contained a StyI site (lower case) and antisense primer nt 3019-
5′CAGTGCgcggccgcCTCAGGTGTC3′ on a unique NotI site (lower case).
All puriﬁed PCR products were cloned into the pGEM-T easy
vector (Promega) and sequenced using selected primers. The as-
sembly of the full-length cDNA clone was done using a multi-step
strategy that implemented the unique restriction sites NdeI, StyI,
NotI, EcoRI and EcoRV on pGEM vectors. Each step of the construction
was monitored by restriction enzyme analysis to ensure the genera-
tion of fragments of predicted sizes. The ﬁnal plasmid containing the
genome-length cDNA of FMDV O1Campos/Bra/58 was designated as
pO1Ca and completely sequenced using an Applied Biosystems 3730
xl automated DNA sequencer (Applied Biosystems, Foster City, CA).
Substitution of aa H56 in the structural protein VP3 was carried
out by site-directed mutagenesis in plasmid pO1Ca using the
QuickChange system (Stratagene) and forward primer nt 2695-5′
GGCATGCCCGACGTTTCTGCGCTTCGAGGGT GGCGTACCGTAC3′ con-
taining the desired change (in bold), following the manufacturer's
protocol. The full-length mutant clone was completely sequenced
to conﬁrm the presence of expected modiﬁcations and absence of
unwanted substitutions.
Transfection and recovery of the infectious clone-derived viruses
Plasmid pO1Ca or its mutant version was linearized at the EcoRV
site following the poly(A) tract and used as a template for RNA
synthesis using the MegaScript T7 kit (Ambion, Austin, TX), according
44 M.V. Borca et al. / Virology 422 (2012) 37–45to the manufacturer's protocols. BHK-21 cells were transfected with
these synthetic RNAs by electroporation (Electrocell Manipulator 600;
BTX, SanDiego, CA) as previously described (Mason et al., 1994). Brieﬂy,
0.5 ml of BHK-21 cells at a concentration of 1.5×107 cells/ml in phos-
phate-buffered saline (PBS) were mixed with 10 μg of RNA in a 4-
mm-gap BTX cuvette. The cells were then pulsed once at 330 V, inﬁnite
resistance, and a capacitance of 1000 μF; diluted in cell growthmedium
and allowed to attach to a T-25 ﬂask. After 4 h, the medium was
removed, fresh medium was added and the cultures were incubated
at 37 °C for up to 24 h.
The supernatants from transfected cells were passed in LF-BK
αVβ6 cells until a cytopathic effect (CPE) appeared. After successive
passages in these cells, virus stocks were prepared and the viral
genome completely sequenced using the Prism 3730xl automated
DNA sequencer (Applied Biosystems), as previously described (Piccone
et al., 2010).
Viruses derived from plasmid pO1Ca and the derived mutant
plasmid encoding the aa substitution H56R in VP3 are referred to
in this work as O1Ca-VP3-56H and O1Ca-VP3-56R, respectively.In vitro processing
Plasmid pO1Ca containing the complete genome sequence was
linearized with EcoRV and in vitro transcribed using the T7-based
MegaScript kit (Ambion, Inc., Austin, Tex.). RNA transcripts were
translated in vitro by using rabbit reticulocyte lysates (Promega,
Fitchburg, WI) in the presence of [35S] methionine and translation
reaction mixtures were resolved by electrophoresis on 15% polyacryl-
amide gels containing sodium dodecyl sulfate (SDS-PAGE) and ﬂuoro-
graphed, following previously described procedures (Piccone et al.,
1995). Additionally, pO1Ca was digested with selected restriction
enzymes that eliminate part of the viral open reading frame, and
used in in vitro transcription/translation assaysVirulence of O1Ca-VP3-56H or O1Ca-VP3-56R viruses in cattle and swine
Animal experiments were performed under biosafety level 3 condi-
tions in the animal facilities at PIADC following a protocol approved by
the Institutional Animal Care and Use Committee. Two steers (300–
400 kg) were infected per the intradermolingual inoculation method
(Henderson, 1949) with approximately 104 PFU/cattle of FMDV O1Ca-
VP3-56H or O1Ca-VP3-56R, diluted in MEM. Six pigs (20 kg) were
infected intradermally (Pacheco and Mason, 2010) with 104 PFU/pig
of either FMDV O1Ca-VP3-56H or O1Ca-VP3-56R, diluted in MEM. For
7 days after inoculation, animals were clinically examined, including
rectal temperature recordings and serum and nasal swabs collection.
After collection, clinical samples were aliquotted and frozen at
−70 °C. One serum and one swab aliquot were used to perform viral ti-
tration by rRT-PCR as described previously (Pacheco et al., 2010). For
cattle, clinical scoring was made based on lesions present in each foot,
with amaximumof 4. For swine, the clinical scorewasbased on severity
of affected digits and/or snout, as previously described (Pacheco and
Mason, 2010), with a maximum of 20.Acknowledgments
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